The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

• Hannah M. Cherniawsky,
• Vishal Kukreti,
• Donna Reece,
• Esther Masih-Khan,
• Arleigh McCurdy,
• Victor H. Jimenez-Zepeda,
• Michael Sebag,
• Kevin Song,
• Darrell White,
• Julie Stakiw,
• Richard LeBlanc,
• Anthony Reiman,
• Muhammad Aslam,
• Martha Louzada,
• Rami Kotb,
• Engin Gul,
• Eshetu Atenafu,
• Christopher P. Venner

Affiliations

Hannah M. Cherniawsky

University of Alberta, Edmonton, Alberta

Vishal Kukreti

Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON

Donna Reece

Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON

Esther Masih-Khan

Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Canadian Myeloma Research Group, Toronto, Ontario

Arleigh McCurdy

The Ottawa Hospital, Ottawa, Ontario

Victor H. Jimenez-Zepeda

Tom Baker Cancer Centre, Calgary, Alberta

Michael Sebag

Department of Oncology, Division of Hematology, McGill University, Montreal, QC

Kevin Song

BC Cancer, Vancouver General Hospital, British Columbia

Darrell White

Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia

Julie Stakiw

Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan

Richard LeBlanc

Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec

Anthony Reiman

Department of Oncology, Saint John Regional Hospital, Saint John, NB

Muhammad Aslam

Allan Blair Cancer Centre, Regina, Saskatchewan

Martha Louzada

London Regional Cancer Center, London, Ontario

Rami Kotb

Cancer Care Manitoba, Winnipeg, Manitoba

Engin Gul

Canadian Myeloma Research Group, Toronto, Ontario

Eshetu Atenafu

Canadian Myeloma Research Group, Toronto, Ontario

Christopher P. Venner

Cross Cancer Institute, University of Alberta, Edmonton, Alberta